Serina Therapeutics
22 hedge funds and large institutions have $822K invested in Serina Therapeutics in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.48% less ownership
Funds ownership: 4.5% → 4.03% (-0.48%)
12% less funds holding
Funds holding: 25 → 22 (-3)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
67% less capital invested
Capital invested by funds: $2.48M → $822K (-$1.65M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.7K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$14.6K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.24K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
-$116K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$25.2K |
| 3 |
Citigroup
New York
|
-$12.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.3K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.84K |
SER Hedge Fund Activity: Q4 2025 in Review
22 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q4 2025, worth a combined $822K — down 67% from $2.48M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SER and 0 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was BlackRock, adding an estimated $16.7K. The largest seller was Broadwood Capital, cutting an estimated $116K.
- 22 institutional investors held Serina Therapeutics (SER) as of Q4 2025, down from 25 in Q3 2025.
- Funds reported $822K of Serina Therapeutics stock for Q4 2025, down 67% quarter-over-quarter.
- 0 funds opened new Serina Therapeutics positions in Q4 2025 and 3 closed out, a net change of -3 holders.
- The largest Serina Therapeutics buyer in Q4 2025 was BlackRock, an estimated $16.7K added.
- The largest Serina Therapeutics seller in Q4 2025 was Broadwood Capital, an estimated $116K sold.
Based on aggregated 13F filings for Q4 2025.